AlphaMaven

Company Logo'

Venture Capital

BioHealth Capital Fund

Healing the World One Investment at a Time
Back

Venture Capital

BioBuzz - A Deeper Dive Into The BioHealth Capital Region’s #4 Spot On GEN’s Top 10 U.S. Biopharma Clusters List

posted by BioHealth Capital Fund
6mos ago 512

To read the entire article click here.


It has been a banner year for the biopharma industry in the BioHealth Capital Region (BHCR), marked most notably by a large increase in VC deals. It was this increase in investment activity that was largely why the region reclaimed it’s #4 ranking on GEN’s Top 10 U.S. Biopharma Clusters List again this year. JLL reports $1.1B in VC investment over 44 deals this past year, the largest of which being the $250 million Series A financing by MedImmune spin-out Viela Bio.


Below are the rankings for the five categories GEN evaluates to calculate their comparison.


BioHealth Capital Region Rankings

VC: 3rd (JLL reports 44 deals for $1.1 billion)


NIH Funding: 3rd (3103 awards totaling $1.456 billion)


Patents: 3rd (4943, just 32 ahead of San Diego)


Lab Space: 4th (22.5 million square feet according to Scheer Partners)


Employment: 9th (JLL reports the region to have 41,322 sector jobs)


The number four spot is one that is rightfully earned as a result of the increased connectivity and regional collaboration that has picked up over the last four years in an effort lead by MedImmune and BioHealth Innovation to become a Top 3 Biopharma Hub by 2023. Historically, the BHCR and San Diego have battled back in forth every year for that #4 spot since 2015, as can be seen in the year-over-year timeline illustrated below.


One thing that stood out more than the ranking this year was that it was the first year that GEN recognized the “BioHealth Capital Region” as the name of the cluster, as opposed to “Maryland / Virginia / DC Metro” or “Maryland / Suburban Washington D.C.” which it had been named in the past. Insiders will recognize that this is an indication that the “brand” is now becoming more widely accepted across the industry when talking about this cluster.


To read the entire article click here.


ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.